Tumor cells in PCL are generally considered to express higher levels of CD19, CD20 and CD45 than those in MM (38, 39); similarly, upward expression of these biomarkers were observed in CPC than their BM counterparts (30). Here, CD19 is linked to Miyoshi myopathy.